DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/c8n9xw/multiple_myeloma) has announced the addition of the "Multiple Myeloma Pipeline Highlights - 2015" report to their offering.
The latest report Multiple Myeloma Pipeline Highlights - 2015, provides most up-to-date information on key pipeline molecules in the global Multiple Myeloma market. It covers emerging therapies for Multiple Myeloma in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.
Clinical Trial Stages:
The report provides Multiple Myeloma pipeline molecules by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.
Drug Mechanism Classes:
The report provides Multiple Myeloma pipeline molecules by their dominant mechanism of action. This helps executives categorize molecules based on their drug class and also assess the strengths and weaknesses of compounds.
The report provides Multiple Myeloma pipeline molecules by the Originator Company.
Short-term Launch Highlights:
Find out which Multiple Myeloma pipeline products will be launched in the US and Ex-US till 2017.
Key Topics Covered:
1. Multiple Myeloma Pipeline by Stages
2. Multiple Myeloma Pipeline by Drug Class
3. Multiple Myeloma Pipeline by Company
4. Multiple Myeloma Phase 3 Clinical Trial Insights
5. Multiple Myeloma Phase 2 Clinical Trial Insights
6. Multiple Myeloma Phase 1 Clinical Trial Insights
7. Multiple Myeloma Preclinical Research Insights
8. Multiple Myeloma Discovery Stage Insights
10. Research Methodology
For more information visit http://www.researchandmarkets.com/research/c8n9xw/multiple_myeloma